Other analysts also recently issued research reports about the stock. Zacks Investment Research upgraded shares of Atyr Pharma from a hold rating to a buy rating and set a $4.00 target price for the company in a report on Tuesday, August 16th. Citigroup Inc. lifted their target price on shares of Atyr Pharma from $3.00 to $4.00 and gave the company a neutral rating in a report on Tuesday, August 16th. Finally, JPMorgan Chase & Co. dropped their target price on shares of Atyr Pharma from $15.00 to $10.00 and set an overweight rating for the company in a report on Thursday, August 11th. Three analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. The company presently has a consensus rating of Hold and an average price target of $6.50.
Atyr Pharma (NASDAQ:LIFE) opened at 3.04 on Thursday. The company has a 50 day moving average price of $3.13 and a 200 day moving average price of $3.24. Atyr Pharma has a 52-week low of $2.48 and a 52-week high of $13.26. The firm’s market capitalization is $72.10 million.
Atyr Pharma (NASDAQ:LIFE) last posted its earnings results on Wednesday, August 10th. The company reported ($0.65) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.71) by $0.06. On average, equities analysts forecast that Atyr Pharma will post ($2.56) EPS for the current fiscal year.
A number of institutional investors have recently modified their holdings of the stock. GSA Capital Partners LLP purchased a new stake in Atyr Pharma during the second quarter valued at about $101,000. A.R.T. Advisors LLC boosted its stake in Atyr Pharma by 88.8% in the second quarter. A.R.T. Advisors LLC now owns 39,143 shares of the company’s stock valued at $108,000 after buying an additional 18,410 shares during the period. Bridgeway Capital Management Inc. purchased a new stake in Atyr Pharma during the second quarter valued at about $133,000. Jackson Park Capital LLC purchased a new stake in Atyr Pharma during the second quarter valued at about $183,000. Finally, State Street Corp boosted its stake in Atyr Pharma by 51.8% in the first quarter. State Street Corp now owns 68,285 shares of the company’s stock valued at $270,000 after buying an additional 23,290 shares during the period. 44.75% of the stock is owned by institutional investors.
About Atyr Pharma
aTyr Pharma, Inc is a clinical-stage biotherapeutics company. The Company is engaged in the discovery and clinical development of medicines for patients suffering from severe, rare diseases using its Physiocrine biology, a discovered set of physiological modulators. The Company focuses on the development of Physiocrine-based therapeutics for the treatment of rare diseases, including facioscapulohumeral muscular dystrophy (FSHD) and limb-girdle muscular dystrophy (LGMD) 2B.
Receive News & Ratings for Atyr Pharma Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atyr Pharma Inc. and related companies with MarketBeat.com's FREE daily email newsletter.